Sublingual vs. Oral Absorption: How Many Times Better Is It, Really?

A reader asked me last week: "If a sublingual strip is so much better than a pill, how much better is it?"

It's a fair question, and the marketing answer ("10x faster!") is almost always wrong. The honest answer is that the multiplier depends entirely on which molecule is in the strip. For some active ingredients the bioavailability gain is modest — around 1.2x. For others, the difference is 30-fold or more.

As a pharmacist formulating sublingual strips for a living, I want to walk through what the peer-reviewed literature actually says, with citations. No marketing language. Just the numbers.

The "first-pass" problem in plain terms

When you swallow a capsule, the active ingredient travels: mouth → stomach → small intestine → portal vein → liver → systemic circulation. The last two steps are where most of the dose is lost.

The liver does two jobs the moment a compound arrives: it filters and it metabolizes. For some drugs, the liver destroys 50%, 70%, even 99% of what was swallowed before any of it reaches the bloodstream. Pharmacology textbooks call this the "first-pass effect," and it's the single biggest reason oral bioavailability is usually a fraction of the labeled dose (Herman & Santos, StatPearls, 2023).

Sublingual delivery routes around the liver entirely. A molecule absorbed through the floor of the mouth enters the sublingual venous plexus, drains into the internal jugular vein, returns to the heart, and reaches the rest of the body without ever passing through hepatic metabolism on the way in (Tian et al., Pharmaceutics, 2023).

That single mechanical difference is the entire reason sublingual delivery exists as a pharmacological strategy. The question is just how much it matters for any given compound.

What the studies actually measured

I pulled the head-to-head comparison data from the peer-reviewed literature. Here is the picture:

A few observations are worth making explicit.

First, the multiplier scales with how badly the compound is destroyed in the liver. Nitroglycerin is the textbook extreme — almost the entire oral dose is gone before it reaches the bloodstream, so sublingual delivery effectively recovers a 38-fold loss. Compounds that are already well-absorbed orally (such as caffeine, which is nearly 100% bioavailable through the gut) don't show a dramatic AUC gain — but they can still benefit in speed.

Second, speed and total dose are two different metrics. Kamimori's study of caffeine chewing gum at 50-200 mg doses found that absorption rate was significantly faster from the buccal mucosa, even though the eventual total absorbed amount was similar to swallowed caffeine at higher doses (Kamimori et al., 2002). For an active ingredient where users care about onset (caffeine, melatonin, anything for acute relief), faster Tmax matters more than total AUC.

Third, the 2023 Bartoli study is the cleanest melatonin comparison I've seen. Fourteen healthy adults received either a prolonged-release tablet (1.9 mg) or an immediate-release sublingual spray (1 mg) in a crossover design. After correcting for dose, sublingual spray delivered 1.89 times the bioavailability of the swallowed tablet (Bartoli et al., 2023). For a hormone-like compound with a famously short half-life, that's a meaningful difference.

Why sublingual delivery works mechanically

Three properties of the oral mucosa make this route work, and they are worth knowing because they also define its limits.

Permeability. The mucosal lining of the mouth is roughly 4 to 1,000 times more permeable than skin, depending on the region and the molecule (Khurana et al., J Pharm Res, 2017). The sublingual area specifically has a thinner, non-keratinized epithelium, which is one of the most permeable sites in the body (Tian et al., 2023).

Vascularization. Underneath that thin epithelium is a dense capillary bed feeding directly into the jugular venous return. Compounds that cross the epithelium are essentially injected straight into circulation, bypassing the GI tract entirely (Tian et al., 2023).

Bypass of GI degradation. Beyond the liver, the gut wall and stomach acid degrade many sensitive compounds before they're ever absorbed. CYP3A4 in the intestinal wall alone accounts for a significant fraction of the oral first-pass loss for compounds like triazolam (Scavone et al., 1995). Sublingual delivery skips all of it.

Why I formulated MIHIYO products as ODS specifically

There are several sublingual delivery formats — sprays, lozenges, drops, films, gum. I chose oral dissolving strips (ODS) for MIHIYO Labs for specific reasons that came out of the formulation literature:

1. Strips remain in place. Sprays can be swallowed reflexively, which routes a fraction of the dose right back through the liver. A film adheres to the mucosa and dissolves over 30-90 seconds while the dose actually crosses.
2. Dose precision. Each strip carries an exact amount of active ingredient. Sprays vary with propellant pressure and user technique; gum varies with chewing time.
3. No water needed. Useful in travel, exercise, or any context where a glass of water isn't available.
4. Patient compliance data. Across the formulation literature, oral fast-dissolving films consistently report higher adherence than swallowed tablets, especially in older or younger users (Eltabeeb et al., 2021).

The active ingredients in the three current MIHIYO products were chosen because each one has a plausible mechanistic reason to benefit from mucosal delivery:

I want to be careful here. None of the studies above were conducted on MIHIYO products specifically. They were conducted on the molecules themselves, in research formulations. What the data tells us is that the mechanism favors mucosal delivery — not that any specific commercial strip outperforms any specific commercial capsule by exactly some number.

The honest limits

A short list of things sublingual delivery cannot fix, because every formulation article skipping these is doing readers a disservice:

• Saliva washes material away. The mouth produces 0.5–1.5 L of saliva per day. Anything that doesn't cross the mucosa quickly is swallowed. Film formulations are designed to manage this, but it's a real ceiling on total dose absorbed sublingually (Tian et al., 2023).
• Large molecules don't cross. Peptides above ~1,000 Daltons typically need permeation enhancers or nanoencapsulation to absorb sublingually at meaningful rates (Squier & Wertz, 1993). This is one reason injectable peptides remain injectable.
• Lipophilicity matters. Compounds need a balance of water solubility (to dissolve in saliva) and lipophilicity (to cross the epithelial cells). This is one of the engineering constraints I work with at the formulation stage.
• Dose saturation. The Bartoli melatonin study noted that beyond a certain dose, sublingual absorption saturates and the excess gets swallowed and metabolized by the liver after all (Bartoli et al., 2023). This is why dose-stacking sublingual strips doesn't scale linearly.

The bottom line

If someone asks me "how many times better is sublingual absorption than swallowing?" the honest answer is:

• For compounds heavily destroyed by the liver (nitroglycerin, some peptide-like molecules): 10x to 40x.
• For compounds with moderate first-pass loss (melatonin, paroxetine, triazolam): roughly 1.2x to 2x in total bioavailability, plus faster onset.
• For compounds that are already well-absorbed orally (caffeine): roughly equivalent in AUC, but meaningfully faster Tmax.

Sublingual delivery is not a cheat code that makes any supplement two times better. It is a route-of-administration strategy with a specific mechanism — bypassing the gut and liver — that pays off most for molecules where that bypass actually matters. I formulate around that reality at MIHIYO. The strips I design are not for every active ingredient — they are for the ones where the mucosal route changes the math.

If you want to read the underlying papers, they're listed below with direct links to PubMed and the journals.

References

1. Scavone JM, Greenblatt DJ, Friedman H, Shader RI. Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. Pharmacology / Clin Pharmacol Ther. 1995. PMID: 7593708. https://pubmed.ncbi.nlm.nih.gov/7593708/

2. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781-784. https://pubmed.ncbi.nlm.nih.gov/10883420/

3. Kamimori GH, Karyekar CS, Otterstetter R, et al. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. International Journal of Pharmaceutics. 2002;234(1-2):159-167. https://doi.org/10.1016/S0378-5173(01)00958-9

4. Herman TF, Santos C. First-Pass Effect. StatPearls Publishing, NCBI Bookshelf. Updated 2023. NBK551679. https://www.ncbi.nlm.nih.gov/books/NBK551679/

5. Bartoli AN, De Gregori S, Molinaro M, et al. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs in R&D. 2023. DOI: 10.1007/s40268-023-00431-9. https://link.springer.com/article/10.1007/s40268-023-00431-9

6. Hines RM, Khumnark M, Macphail B, Hines DJ. Administration of Micronized Caffeine Using a Novel Oral Delivery Film Results in Rapid Absorption and Electroencephalogram Suppression. Frontiers in Pharmacology. 2019;10:983. DOI: 10.3389/fphar.2019.00983. https://www.frontiersin.org/articles/10.3389/fphar.2019.00983/full

7. Tian Y, Bhide YC, Woerdenbag HJ, et al. Oral Mucosa Models to Evaluate Drug Permeability. Pharmaceutics.2023;15(5):1559. DOI: 10.3390/pharmaceutics15051559. PMC10220859. https://www.mdpi.com/1999-4923/15/5/1559

8. Eltabeeb MA, Hamed RR, El-Nabarawi MA, Teaima MH. Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers.Pharmaceutics. 2021. PMC8620498. https://pmc.ncbi.nlm.nih.gov/articles/PMC8620498/

9. Khurana S, Madhav NV, Tangri P. Orally Disintegrating Strips: A New Approach to Oral Drug Delivery System. Journal of Pharmaceutical Research. 2017;16(3):257. (Discussion of oral mucosal permeability vs skin)

10. Squier CA, Wertz PW. Permeability and the pathophysiology of oral mucosa. Advanced Drug Delivery Reviews.1993;12(1-2):13-24. https://doi.org/10.1016/0169-409X(93)90038-7